ZEISS Medical Ecosystem - Digital Solutions Roll-out
Ophthalmology
Topline growth primarily driven by accelerating deliveries of devices
6M 2022/23
6M 2021/22
651.9
6M 2022/23
6M 2021/22
MCS
0
Carl Zeiss Meditec Group
€ 742.6 million
+13.9%
Revenue
"
FX-adj. revenue growth of +12.3%
Delivery of devices accelerated towards end of reporting period, slight supply chain
improvements, growth in devices outpaced consumables
Weaker product mix mainly caused by COVID-19 infection wave in China, strong recovery
towards the end of the period, positive outlook for main season for refractive procedures
EBIT margin
EBIT margin decline affected by:
12.3%
-7.1 pps
Weaker product mix due to slower consumables growth
19.4%
Continued high level of strategic investment in research & development
and sales & marketing
76.2%
OPT
of total revenue
Revenue Split
I
ZEISS
Page 23View entire presentation